Immunomedics Warns Biosimilar Chasers Over Trodelvy
Sacituzumab Biologic Brand Was Approved By FDA In April
Biosimilar sponsors know well the challenges to approval. Immunomedics, which in April obtained FDA approval for the Trodelvy oncology biologic, has suggested the barriers for competitors to the brand may be insurmountable for some time.
You may also be interested in...
Acquisition is based on the prospects for Immunomedics’ Trodelvy, but regulatory changes, manufacturing challenges, and research dynamics could upset even the best-laid plans.
Trodelvy was granted an accelerated approval by the US FDA based on a Phase II study. It is the first commercial product for Immunomedics.
Sponsors may submit supplemental applications for additional indications in advance so that approval will coincide with expiration of a reference product’s exclusivity or patent protection, new draft guidance states; agency targets six-month review of such supplements, rather than the 10 months provided under BsUFA II.